Team:UIUC Illinois/project-overview

From 2012e.igem.org

(Difference between revisions)
Line 29: Line 29:
       <p>The two product lines being developed by Illinois Synth are as follows:</p>
       <p>The two product lines being developed by Illinois Synth are as follows:</p>
         <ul>
         <ul>
-
             <li class="bullet">-  Gene Expression Modulator (GEM) Toolkit – a PUF protein domain-based customizable ssRNA-specific toolkit to modulate and regulate gene expression.</li>
+
             <li class="bullet">Gene Expression Modulator (GEM) Toolkit – a PUF protein domain-based customizable ssRNA-specific toolkit to modulate and regulate gene expression.</li>
             <img src="" style="float: right;"/>
             <img src="" style="float: right;"/>
-
             <li class="bullet">-  In Vivo Optimized Piceatannol Cascade (IOPiC) – an RNA-scaffold based enzymatic conveyer belt designed to produce piceatannol from L-tyrosine.</li>
+
             <li class="bullet">In Vivo Optimized Piceatannol Cascade (IOPiC) – an RNA-scaffold based enzymatic conveyer belt designed to produce piceatannol from L-tyrosine.</li>
             <img src="" style="float: right;"/>
             <img src="" style="float: right;"/>
         </ul>
         </ul>
Line 39: Line 39:
       <p>Our competitive analysis was broken into two components:</p>
       <p>Our competitive analysis was broken into two components:</p>
       <ul>
       <ul>
-
           <li class="bullet">-  Analysis of alternative RNA-binding proteins</li>
+
           <li class="bullet">Analysis of alternative RNA-binding proteins</li>
-
           <li class="bullet">-  Analysis of alternative ways to produce piceatannol</li>
+
           <li class="bullet">Analysis of alternative ways to produce piceatannol</li>
 +
      </ul>
 +
      <p>Analysis of alternative ways to bind to RNA yielded protein domains that are not as site specific as the PUF domain (8 nucleotide sequence specificity), and/or are uncustomizable whereas PUF can be programmed to  recognize a desired ssRNA sequence while being tethered to a functional domain such as an endonuclease.</p>
 +
      <p>Chemical synthesis is the only current mode of production of piceatannol, and has proven to be expensive due to the inefficiency of the chemical process. Tocris Bioscience, in particular, has a base rate of $19/mg of piceatannol. Additionally, instead of competing directly with large pharmaceutical companies to produce piceatannol at a low cost, we intend to license our technology to companies interested in using our RNA scaffold.</p>
 +
      <h3>Value Proposition</h3>
 +
      <p>Our GEM Toolkit will provide an extremely novel, and efficient way to regulate and modulate gene expression in ssRNA. We expect such a toolkit to provide a high degree of utility to researchers interested in varying gene expression levels. Additionally, we believe IOPiC will provide a low cost, biological alternative to achieve the production of piceatannol without involving expensive chemical processes.</p>
 +
      <h3>Marketing and Sales Plan</h3>
 +
      <p>Illinois Synth will adopt a two-step marketing plan for its GEM Toolkit and IOPiC technologies. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price products. The specifics of the marketing strategy, including online marketing are detailed throughout the plan.</p>
 +
      <h3>Management and Organization</h3>
 +
      <p>Illinois Synth’s management board brings with it the ability to raise venture capital, make necessary contacts with representatives from academia and industry, and develop our products methodically through cutting-edge research and development. The board members come from a variety of scientific and engineering backgrounds, and also have the business development experience to set up the necessary infrastructure for Illinois Synth. In addition to the management board, Illinois Synth is advised by an advisory board that represents an exceptional set of professors, graduate students, and researchers from the University of Illinois. Resumes for management board members can be found in the Appendix.</p>
 +
      <h3>Financial Summary</h3>
 +
      <p>Illinois Synth will rely on equity financing, product sales, contract manufacturing, corporate partnerships, and interest income to fund its operations and capital expenditures. Negative cash flow due to research and development of the two product lines is expected to continue for a minimum of 15 months, through the first quarter of 2014. Due to the possible need for additional funds to expand product development, sales, and marketing capabilities, other sources of capital such as venture and angel investments will be explored. Future capital requirements will depend on a variety of factors, including:</p>
 +
      <ul>
 +
          <li>Progress in Research & Product development programs</li>
 +
          <li>Relationships with corporate sponsors</li>
 +
          <li>Relationships with academic or industrial collaborators</li>
 +
          <li>Competing technological and market developments</li>
 +
          <li>Patent filing, prosecuting, and filing costs</li>
 +
          <li>Commercialization activities</li>
 +
          <li>Industry Growth</li>
 +
      </ul>
 +
      <h3>Investor Summary</h3>
 +
      <ul>
 +
          <li>Illinois Synth has a unique, significant and adaptable product line that is expected to generate rapid sales growth in an emerging industry.</li>
 +
          <li>The members of Illinois Synth’s management team have backgrounds in engineering, molecular biology, and business development, making them uniquely suited to address the challenges associated with setting up a synthetic biology enterprise.</li>
 +
          <li>Experienced advisory board including faculty and researchers from the University of Illinois.</li>
 +
          <li>Logistical and technical support from the Institute for Genomic Biology at the University of Illinois, one of the premier biotechnology research institutions in the United States.</li>
       </ul>
       </ul>
       </div>
       </div>

Revision as of 16:58, 27 October 2012

Header

The Company

YOU HAVE 960 PIXELS WIDTH TO PLAY WITH FOR WHATEVER YOU WANT TO EMBED! Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas metus nulla, commodo a sodales sed, dignissim pretium nunc. Nam et lacus neque. Sed volutpat ante id mauris laoreet vestibulum. Nam blandit felis non neque cursus aliquet. Morbi vel enim dignissim massa dignissim commodo vitae quis tellus. Nunc non mollis nulla. Sed consectetur elit id mi consectetur bibendum. Ut enim massa, sodales tempor convallis et, iaculis ac massa. Etiam suscipit nisl eget lorem pellentesque quis iaculis mi mattis. Aliquam sit amet purus lectus. Maecenas tempor ornare sollicitudin.

Executive Summary

The Company

Illinois Synth was formed in June 2012 to develop, market, and license products intended to further the progress of synthetic biology. Our founding team is comprised of six University of Illinois undergraduate students from a variety of backgrounds including bioengineering, biochemistry, molecular biology, agricultural engineering and chemical engineering. Brought together initially by the desire to work with synthetic biology in the context of the International Genetically Engineered Machines (iGEM) competition, we are now in the process of commercializing our research.

The Products

The two product lines being developed by Illinois Synth are as follows:

The Market

Ever since the discovery of restriction enzymes in 1978, a new era of synthetic biology was ushered in, an era in which scientific discovery would meet engineering, and promised the ability to eventually control and modulate gene expression. Illinois Synth has a deep confidence not only in the growth of synthetic biology as an industry, but in the growing demand for technologies that will allow the modulation of gene expression in RNA. Such tools currently take the form of RNA recognition motifs, K Homology proteins, and CCCH Zinc Finger proteins that in many cases do not exhibit sequence specific binding, or are unable to be programmed to recognize specific, desired ssRNA sequences. With regard to the use of an in vivo enzymatic cascade to produce piceatannol, our analysis has shown that such a method would be faster, more efficient, and lower cost than chemical synthesis of the compound, which is the only current mode of production.

Competitive Analysis

Our competitive analysis was broken into two components:

Analysis of alternative ways to bind to RNA yielded protein domains that are not as site specific as the PUF domain (8 nucleotide sequence specificity), and/or are uncustomizable whereas PUF can be programmed to recognize a desired ssRNA sequence while being tethered to a functional domain such as an endonuclease.

Chemical synthesis is the only current mode of production of piceatannol, and has proven to be expensive due to the inefficiency of the chemical process. Tocris Bioscience, in particular, has a base rate of $19/mg of piceatannol. Additionally, instead of competing directly with large pharmaceutical companies to produce piceatannol at a low cost, we intend to license our technology to companies interested in using our RNA scaffold.

Value Proposition

Our GEM Toolkit will provide an extremely novel, and efficient way to regulate and modulate gene expression in ssRNA. We expect such a toolkit to provide a high degree of utility to researchers interested in varying gene expression levels. Additionally, we believe IOPiC will provide a low cost, biological alternative to achieve the production of piceatannol without involving expensive chemical processes.

Marketing and Sales Plan

Illinois Synth will adopt a two-step marketing plan for its GEM Toolkit and IOPiC technologies. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price products. The specifics of the marketing strategy, including online marketing are detailed throughout the plan.

Management and Organization

Illinois Synth’s management board brings with it the ability to raise venture capital, make necessary contacts with representatives from academia and industry, and develop our products methodically through cutting-edge research and development. The board members come from a variety of scientific and engineering backgrounds, and also have the business development experience to set up the necessary infrastructure for Illinois Synth. In addition to the management board, Illinois Synth is advised by an advisory board that represents an exceptional set of professors, graduate students, and researchers from the University of Illinois. Resumes for management board members can be found in the Appendix.

Financial Summary

Illinois Synth will rely on equity financing, product sales, contract manufacturing, corporate partnerships, and interest income to fund its operations and capital expenditures. Negative cash flow due to research and development of the two product lines is expected to continue for a minimum of 15 months, through the first quarter of 2014. Due to the possible need for additional funds to expand product development, sales, and marketing capabilities, other sources of capital such as venture and angel investments will be explored. Future capital requirements will depend on a variety of factors, including:

Investor Summary

Retrieved from "http://2012e.igem.org/wiki/index.php/Team:UIUC_Illinois/project-overview"